The Tumor Biology Program serves as one of the main epicenters of basic cancer research in the Duke Cancer Institute. The two main goals of the Tumor Biology program are to i) foster innovative, high-impact basic approaches to elucidate the molecular mechanisms underpinning cancer and ii) promote collaborative and transdisciplinary research in the field of cancer biology through programmatic seminars, programmatic work-in-progress meetings, annual programmatic retreats, transdisciplinary joint retreats and training initiatives. The Tumor Biology program is led by Drs. Ann Marie Pendergast and Christopher Counter, and is partitioned into the two focus groups: Metabolism and Signaling, led by Drs. Jeff Rathmell and Xiao-Fan Wang, and Stem Cell Biology, led by Drs. Brigid Hogan and John Chute. The program is comprised of 31 primary members and 24 secondary members from a wide spectrum of 13 different departments. Total peer- reviewed funding (Direct + Indirect Costs) for primary program members is $16.3M (represents 70% of total $23.5M funding). $3.6M of the peer-reviewed funding is directly from the NCI. From 2009-2013, program members report 679 publications in peer-reviewed journals cited in PubMed. Of these publications, 5.4% are the result of intra-programmatic collaborations while 23.0% are due to inter-programmatic collaborations, with nearly one quarter of grants categorized by responding principle investigators as cancer-related.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-45
Application #
9620052
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
45
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications